Literature DB >> 20576797

Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.

Gary W Lawrence1, K Roger Aoki, J Oliver Dolly.   

Abstract

Mediators of neuromuscular transmission in rat bladder strips were dissected pharmacologically to examine their susceptibilities to inhibition by botulinum neurotoxins (BoNTs) and elucidate a basis for the clinical effectiveness of BoNT/A in alleviating smooth muscle spasms associated with overactive bladder. BoNT/A, BoNT/C1, or BoNT/E reduced peak and average force of muscle contractions induced by electric field stimulation (EFS) in dose-dependent manners by acting only on neurogenic, tetrodotoxin-sensitive responses. BoNTs that cleaved vesicle-associated membrane protein proved to be much less effective. Acetylcholine (ACh) and ATP were found to provide virtually all excitatory input, because EFS-evoked contractions were abolished by the muscarinic receptor antagonist, atropine, combined with either a desensitizing agonist of P2X(1) and P2X(3) or a nonselective ATP receptor antagonist. Both transmitters were released in the innervated muscle layer and, thus, persisted after removal of urothelium. Atropine or a desensitizer of the P2X(1) or P2X(3) receptors did not alter the rate at which muscle contractions were weakened by BoNT/A. Moreover, although cholinergic and purinergic signaling could be partially delineated by using high-frequency EFS (which intensified a transient, largely atropine-resistant spike in muscle contractions that was reduced after P2X receptor desensitization), they proved equally susceptible to BoNT/A. Thus, equi-potent blockade of ATP co-released with ACh from muscle efferents probably contributes to the effectiveness of BoNT/A in treating bladder overactivity, including nonresponders to anticholinergic drugs. Because purinergic receptors are known mediators of sensory afferent excitation, inhibition of efferent ATP release by BoNT/A could also help to ameliorate acute pain and urgency sensation reported by some recipients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576797     DOI: 10.1124/jpet.110.169342

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Alterations in peripheral purinergic and muscarinic signaling of rat bladder after long-term fructose-induced metabolic syndrome.

Authors:  Shiu-Dong Chung; Chiang-Ting Chien; Hong-Jeng Yu
Journal:  Eur J Nutr       Date:  2012-03-18       Impact factor: 5.614

Review 2.  Botulinum toxin injections for treating neurogenic detrusor overactivity.

Authors:  Ömer Bayrak; Erkan Sadioğlu; Rahmi Onur
Journal:  Turk J Urol       Date:  2015-12

3.  BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity.

Authors:  Mahendra P Kashyap; Subrata K Pore; William C de Groat; Christopher J Chermansky; Naoki Yoshimura; Pradeep Tyagi
Journal:  Am J Physiol Renal Physiol       Date:  2017-11-01

4.  Modulation of purinergic neuromuscular transmission by phorbol dibutyrate is independent of protein kinase C in murine urinary bladder.

Authors:  T J Searl; E M Silinsky
Journal:  J Pharmacol Exp Ther       Date:  2012-04-30       Impact factor: 4.030

Review 5.  Purinergic signalling in the urinary tract in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 6.  Current and potential urological applications of botulinum toxin A.

Authors:  Yuan-Hong Jiang; Chun-Hou Liao; Hann-Chorng Kuo
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

Review 7.  Short- and long-term (trophic) purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-08-05       Impact factor: 6.237

8.  A1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular Transmission in Human and Murine Urinary Bladder.

Authors:  Timothy J Searl; Danuta I Dynda; Shaheen R Alanee; Ahmed M El-Zawahry; Kevin T McVary; Eugene M Silinsky
Journal:  J Pharmacol Exp Ther       Date:  2015-11-03       Impact factor: 4.030

9.  OnabotulinumtoxinA in the treatment of neurogenic bladder.

Authors:  Aziz Gulamhusein; Altaf Mangera
Journal:  Biologics       Date:  2012-08-28

Review 10.  P2X3-Containing Receptors as Targets for the Treatment of Chronic Pain.

Authors:  Jeffrey L Krajewski
Journal:  Neurotherapeutics       Date:  2020-10-02       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.